Cediranib
Cediranib is a tablet that blocks the blood-vessel growth signal VEGF. In alveolar soft part sarcoma, a rare very vascular sarcoma that ignores chemotherapy, a randomised trial showed it shrinks tumours and delays progression, although it was never licensed.
Overview
Cediranib (AZD2171) is AstraZeneca's oral inhibitor of VEGFR-1, -2 and -3. It was tested widely, including the ICON6 trial in relapsed ovarian cancer, but never gained approval. Its clearest activity is in alveolar soft part sarcoma: a National Cancer Institute phase 2 showed responses in a third of patients, and the randomised, placebo-controlled CASPS trial (Lancet Oncology, 2019) found a greater reduction in tumour size at 24 weeks and longer progression-free survival than placebo.
Cediranib remains an investigational drug available in some countries through trials or special access; other VEGFR inhibitors such as sunitinib, pazopanib and anlotinib, and checkpoint inhibitors such as atezolizumab, are used in practice. The alveolar soft part sarcoma page names it among the VEGFR-directed drugs that are active in the disease.
- ATP pocket
- Inhibitor blocks phosphotransfer
- Kinase domain
A potent inhibitor of all three VEGF receptors, with activity against PDGFR and KIT, that blocks tumour angiogenesis; alveolar soft part sarcoma is highly vascular and driven by the ASPSCR1-TFE3 fusion, which upregulates angiogenic genes. Connects to VEGF / VEGFR.
1.Cediranib slips into a pocket on VEGF / VEGFR.
- AmivantamabApproved
- CamizestrantApproved
- Comprehensive genomic profilingStandard of care
- Liquid biopsy (ctDNA)Standard of care
- LorlatinibApproved
- MRD / molecular residual disease testingEstablished
- ADC payload neutralisersPhase 1
- BGB-16673Phase 3
- Bispecific ADCPhase 3
- BRUIN CLL-321Positive
- CaDAnCe-304Recruiting
- CIRCULATE-Japan (GALAXY / VEGA / ALTAIR)Active
- A clone report from blood at every treatment cycle
- A fast route to the matched drug when it is licensed for another cancer
- A multi-cancer platform trial of adaptive (dose-holiday) therapy
- A national rapid research autopsy network for end-stage cancer
- A standard evolvability score for every tumour
- A standing platform trial that assigns treatment by how the tumour escaped
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance atlas · Lines of therapy.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Cediranib" OR ABSTRACT:"Cediranib" OR TITLE:"AZD2171" OR ABSTRACT:"AZD2171" OR TITLE:"Recentin" OR ABSTRACT:"Recentin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Cediranib, not a curated reading list.
Similar pages
not linked directly; found by shared links- TreatmentCarotuximab
Shares Pazopanib and the tag subtype-drugs-wave.
- TreatmentGSK2256098
Shares Small-molecule kinase inhibitors and the tag subtype-drugs-wave.
- TreatmentAnastrozole
Shares AstraZeneca and the tag subtype-drugs-wave.
- TrialClinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
Shares Alveolar soft part sarcoma, Anlotinib.
- Key paperAtezolizumab for advanced alveolar soft part sarcoma
Shares Alveolar soft part sarcoma, Atezolizumab.
- TrialPhase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
Shares Alveolar soft part sarcoma, Anlotinib.
- TrialALTER 0303
- TreatmentVorolanib